Stay updated with breaking news from Renal Response. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Aurinia Pharmaceuticals Inc. today announced that the National Institute for Health and Care Excellence has recommended LUPKYNIS® as an option for treating adults with active lupus nephritis ... | May 3, 2023
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that the National Institute for Health and Care Excellence (NICE) has recommended LUPKYNIS (voclosporin) as an option
Otsuka Pharmaceuticals UK Ltd. announces that the MHRA (Medicines and Healthcare Products Regulatory Agency) has authorised Lupkynis® (voclosporin) for use in combination with mycophenolate mofetil for the treatment of adult patients with active class III, IV or V (including mixed class III/V and IV/V) lupus ...